Kidneya Therapeutics
Kidneya Therapeutics combines innovative healthcare and IT with a vast research base in medicine and metabolomics to develop Artificial Intelligence/Machine Learning deep-learning models for early diagnosis and drug discovery. Their platform functions as a digital biomarker system for patients at risk of Aristolochic Acid exposure, aiding in the monitoring and early diagnosis of Chronic Kidney Disease (CKD). The company leverages AI/ML to combine demographic and clinical data, along with metabolomics research, to create advanced models for identifying new metabolic pathways and developing novel therapies. Their approach utilizes toxins like Aristolochic Acid for drug discovery by analyzing their metabolism.
Kidneya Therapeutics
Kidneya Therapeutics combines innovative healthcare and IT with a vast research base in medicine and metabolomics to develop Artificial Intelligence/Machine Learning deep-learning models for early diagnosis and drug discovery. Their platform functions as a digital biomarker system for patients at risk of Aristolochic Acid exposure, aiding in the monitoring and early diagnosis of Chronic Kidney Disease (CKD). The company leverages AI/ML to combine demographic and clinical data, along with metabolomics research, to create advanced models for identifying new metabolic pathways and developing novel therapies. Their approach utilizes toxins like Aristolochic Acid for drug discovery by analyzing their metabolism.